Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Sight Sciences, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
27.6
49
71.3
81.1
79.9
77.4
Cost of revenue
9.21
8.61
12.4
11.9
11.6
10.7
Gross profit
18.4
40.3
59
69.2
68.3
66.7
Research and development
8.87
15.6
22.9
17.6
18
14.6
Selling, general and administrative
41.7
76.2
120
109
101
89.2
General and administrative
1.8
Operating expenses
50.6
91.8
143
126
119
104
Operating income
-32.2
-51.5
-84
-57.3
-50.5
-37.1
Interest expense
2.4
4.37
4.47
5.41
4.66
5.14
Interest income
0.03
Other non-operating income
-0.07
-6.93
2.23
-0.04
-0.03
-0.15
Pre-tax income
-34.6
-62.8
-86.2
-55.4
-51.3
-38.4
Income tax
0.06
0.19
0.05
0.11
0.24
0.01
Net income
-34.7
-63
-86.2
-55.5
-51.5
-38.4
EBITDA
-31.6
-50.8
-83.2
-56.7
-49.8
-36.6
EPS, basic
-3.71
-2.36
-1.80
-1.14
-1.03
-0.74
EPS, diluted
-3.71
-2.36
-1.80
-1.14
-1.03
-0.74
Shares, basic (weighted)
9.36
26.7
47.8
48.6
50.1
52.1
Shares, diluted (weighted)
9.36
26.7
47.8
48.6
50.1
52.1
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
61.5
261
185
138
120
92
Receivables
5.36
8.71
15.1
14.3
10.8
9.75
Inventory
2.6
3.48
6.11
7.85
6.33
7.77
Other current assets
1.16
4.16
3.42
2.6
2.31
3.26
Total current assets
70.6
277
210
163
140
113
Property, plant and equipment
1.27
1.45
1.57
1.64
1.58
1.61
Lease right-of-use assets
0.52
1.5
1.61
1.46
0.94
0.44
Other non-current assets
0.39
0.2
0.21
0.68
0.55
0.52
Total assets
72.8
280
213
167
143
115
Accounts payable
2.16
3.35
2.69
1.73
1.69
1.34
Accrued liabilities
1.97
2.73
5.31
1.64
2.11
2.14
Short-term debt
0
0
0
2.22
0
0
Total current liabilities
9.31
13.5
17.8
12.3
15.5
11
Long-term debt
32
32.7
33.3
31.7
39.4
40.3
Lease liabilities
0.13
1.04
0.64
0.91
0.47
0
Other non-current liabilities
3.06
1.92
1.87
2.48
0.49
0.03
Total liabilities
44.3
48.1
53
46.4
55.3
51.4
Total debt
32
35
35
35
40
42.4
Paid-in capital
1.18
385
399
415
434
449
Retained earnings
-90
-153
-239
-295
-346
-385
Shareholders' equity
-88.8
232
160
120
87.5
63.9
Total equity
-88.8
232
160
120
87.5
63.9
Total liabilities and equity
72.8
280
213
167
143
115
Shares outstanding
9.51
47.5
48.3
49.1
50.9
53.5
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-34.7
-63
-86.2
-55.5
-51.5
-38.4
Depreciation and amortization
0.55
0.63
0.71
0.61
0.71
0.49
Stock-based compensation
0.5
5.08
13
14.6
17.1
13.1
Change in receivables
-1.48
-3.69
-6.84
0.66
3.55
0.91
Change in inventory
-1.72
-1.31
-3.25
-2.16
1.63
-1.44
Change in payables
0.45
1.17
-0.69
-0.88
0.34
-0.35
Cash from operations
-32.2
-52.5
-76
-47.2
-22.4
-29.7
Capital expenditures
-0.95
-0.81
-0.97
-0.79
-0.39
-0.22
Cash from investing
-0.95
-0.81
-0.97
-0.79
-0.39
-0.22
Debt issued
20.5
0
Stock issued
0.02
0.36
0.58
0.4
0.26
1.09
Cash from financing
73.4
253
1.25
1.1
4.96
1.79
Net change in cash
40.3
199
-75.7
-46.9
-17.8
-28.1
Free cash flow
-33.1
-53.4
-76.9
-48
-22.7
-29.9
Interest paid
1.29
3.11
3.25
4.27
4.26
4.19
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.93 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
88.0%
Gross profit / revenue.
Operating margin
-33.4%
Operating income / revenue.
EBITDA margin
-32.9%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-35.7%
Pre-tax income / revenue.
Net margin
-35.7%
Net income / revenue.
FCF margin
-28.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-27.9%
Cash from operations / revenue.
Return on equity (ROE)
-56.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-28.4%
Net income / average total assets.
Return on invested capital (ROIC)
-158.2%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
13.0%
Research and development expense / revenue.
SG&A / revenue
108.4%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
12.9%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.1%
Capital expenditures / revenue.
D&A / revenue
0.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-3.1%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
2.7%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
22.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-2.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
4.2%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
29.3%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-26.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-26.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-19.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-18.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
9.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
4.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
41.0%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.95x
Current assets / current liabilities.
Quick ratio
4.45x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
3.89x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.77x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
38.9%
Total debt / total assets.
Liabilities / assets
49.6%
Total liabilities / total assets.
Net debt
-$39.0M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.55
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.53
Revenue / diluted weighted shares.
FCF per share
-$0.43
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.43
Cash from operations / diluted weighted shares.
Book value per share
$0.97
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
5.90x
Market cap / revenue.
P/B
9.30x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
9.30x
Market cap / tangible book value, when positive.
EV/Sales
5.43x
Enterprise value / revenue.
FCF yield
-4.7%
Free cash flow / market cap.
Earnings yield
-6.0%
Net income / market cap (the inverse of P/E).
What was Sight Sciences, Inc.'s revenue in fiscal 2025?
Sight Sciences, Inc. reported revenue of $77.4M for fiscal 2025, 3.1% lower than the year before.
Was Sight Sciences, Inc. profitable in fiscal 2025?
No. It reported a net loss of $38.4M.
How much free cash flow did Sight Sciences, Inc. generate in fiscal 2025?
Cash from operations of $29.7M minus capital expenditures of $224.0K left free cash flow of -$29.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.